Addiction rehab monitoring assay
Answers from the Lab
Mayo Clinic Laboratories now offers a comprehensive addiction rehabilitation monitoring profile, an innovative assay that employs a combination of technologies to test urine for the most commonly used substances. In this test specific episode of the "Answers From the Lab" podcast, Loralie Langman, Ph.D., and Paul Jannetto, Ph.D., discuss the test’s utility to help guide and monitor treatment.
“Urine drug testing has been referred to as the technology of addiction treatment,” Dr. Jannetto says. “It’s not meant to be punitive, but rather as a tool to support recovery and provide motivation or reinforcement for abstinence.”
Developed for clinicians who manage complex patients struggling with substance use disorders to common substances such as opioids, marijuana, alcohol, and nicotine, the addiction monitoring profile offers improved specificity and includes adulterant testing and enhanced reports. Listen to learn more about how our testing enables accurate answers and simplified results to clarify patients’ substance use.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Specimen Type: Urine Container, 60 mL (T313)
Specimen Volume: 30 mL
Container/Tube: Plastic urine container
Analytic time: 2 to 5 days
Days performed: Varies
Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' expanded movement disorders panel better identifies autoimmune conditions to guide appropriate treatment.
Cristiane (Cris) Ida, M.D., explains how Mayo Clinic Laboratories' updated neuro-oncology gene panel provides more clinically relevant information for managing adult and pediatric brain tumors.
Melissa Snyder, Ph.D., explains how Mayo Clinic Laboratories' EDN panel improves the evaluation of certain patients with asthma and autoimmune digestive disorders. EDN is the first laboratory test that provides a marker of eosinophil-derived neurotoxins.